Atria Investments Inc Sells 27,858 Shares of Haleon plc (NYSE:HLN)

Atria Investments Inc reduced its stake in shares of Haleon plc (NYSE:HLN) by 13.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 177,885 shares of the company’s stock after selling 27,858 shares during the quarter. Atria Investments Inc’s holdings in Haleon were worth $1,882,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also added to or reduced their stakes in the company. AE Wealth Management LLC lifted its position in Haleon by 6.1% in the second quarter. AE Wealth Management LLC now owns 19,199 shares of the company’s stock worth $159,000 after buying an additional 1,098 shares during the last quarter. Cardinal Capital Management grew its stake in shares of Haleon by 2.5% during the second quarter. Cardinal Capital Management now owns 46,231 shares of the company’s stock worth $382,000 after acquiring an additional 1,140 shares during the last quarter. Lake Street Advisors Group LLC grew its stake in shares of Haleon by 5.4% during the third quarter. Lake Street Advisors Group LLC now owns 22,395 shares of the company’s stock worth $237,000 after acquiring an additional 1,143 shares during the last quarter. Endowment Wealth Management Inc. grew its stake in shares of Haleon by 9.9% during the second quarter. Endowment Wealth Management Inc. now owns 12,867 shares of the company’s stock worth $106,000 after acquiring an additional 1,161 shares during the last quarter. Finally, Portside Wealth Group LLC boosted its position in Haleon by 2.7% in the second quarter. Portside Wealth Group LLC now owns 44,985 shares of the company’s stock valued at $372,000 after buying an additional 1,182 shares during the last quarter. 6.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

HLN has been the subject of several research analyst reports. Morgan Stanley upped their target price on Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a research note on Friday, September 20th. The Goldman Sachs Group cut Haleon from a “buy” rating to a “neutral” rating in a report on Tuesday, August 6th. Berenberg Bank started coverage on Haleon in a research report on Tuesday, August 6th. They issued a “buy” rating on the stock. Finally, UBS Group raised Haleon to a “strong-buy” rating in a research report on Tuesday, October 1st. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $10.95.

Haleon Stock Up 0.9 %

HLN opened at $9.39 on Friday. Haleon plc has a 12 month low of $7.89 and a 12 month high of $10.80. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. The stock has a market cap of $42.51 billion, a P/E ratio of 27.62, a P/E/G ratio of 2.79 and a beta of 0.30. The stock’s 50 day moving average price is $10.10 and its 200 day moving average price is $9.33.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.